Dyskinesia, Drug-Induced (diagnostic imaging) < Dyskinesia, Drug-Induced (drug therapy) < Dyskinesia, Drug-Induced (epidemiology)

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 24.
[0-20] [0 - 20][0 - 24][20-23][20-40]

Ident.	Authors (with country if any)	Title
000123 (????)	A. Hadj Tahar [Canada] ; L. Grégoire ; E. Bangassoro ; P J Bédard	Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys.
000260 (2003)	A. Hadj Tahar [Canada] ; R. Grondin ; L. Grégoire ; F. Calon ; T. Di Paolo ; P J Bédard	New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
000408 (2004)	Abdallah Hadj Tahar [Canada] ; Laurent Grégoire ; Aurélie Darré ; Nancy Bélanger ; Leonard Meltzer ; Paul J. Bédard	Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
000459 (2004)	Yoshiaki Furukawa [Canada] ; James J. Filiano ; Stephen J. Kish	Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
000490 (2005)	Tom H. Johnston [Canada] ; Joohyung Lee ; Jordi Gomez-Ramirez ; Susan H. Fox ; Jonathan M. Brotchie	A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
000657 (1991)	B. Gomez-Mancilla [Canada] ; P J Bédard	Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
000864 (2008)	Leonardo Cortese [Canada] ; Michael P. Caligiuri ; Richard Williams ; Peter Schieldrop ; Rahul Manchanda ; Ashok Malla ; Raj Harricharan	Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.
000952 (2008)	Susan H. Fox [Canada] ; Rosalind Chuang ; Jonathan M. Brotchie	Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
000C87 (2010)	A Jon Stoessl	Continuous dopaminergic therapy in Parkinson disease: time to stride back?
000F27 (2011)	Philippe Huot [Canada] ; Susan H. Fox ; Adrian Newman-Tancredi ; Jonathan M. Brotchie	Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?
000F57 (2011)	Jonathan Brotchie [Canada] ; Peter Jenner	New approaches to therapy.
000F94 (2012)	Laure Chagniel [Canada] ; Christine Robitaille ; Manon Lebel ; Michel Cyr	Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
001221 (2013)	Nicolas Morin [Canada] ; Laurent Grégoire ; Marc Morissette ; Sandrine Desrayaud ; Baltazar Gomez-Mancilla ; Fabrizio Gasparini ; Thérèse Di Paolo	MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
001287 (2013)	Vincent A. Jourdain [Canada] ; Laurent Grégoire ; Marc Morissette ; Nicolas Morin ; Martin Parent ; Thérèse Di Paolo	Potentiation of response to low doses of levodopa in MPTP-injected monkeys by chemical unilateral subthalamotomy.
001353 (2013)	James B. Koprich [Canada] ; Philippe Huot ; Susan H. Fox ; Keith Jarvie ; Anthony E. Lang ; Philip Seeman ; Jonathan M. Brotchie	The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.
001374 (2014)	Nicolas Morin [Canada] ; Vincent A. Jourdain [Canada] ; Thérèse Di Paolo [Canada]	Modeling dyskinesia in animal models of Parkinson disease.
001410 (2013)	Jean-François Daneault [Canada] ; Benoit Carignan [Canada] ; Abbas F. Sadikot [Canada] ; Michel Panisset [Canada] ; Christian Duval [Canada]	Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?
001527 (2013)	Susan H. Fox [Canada]	Non-dopaminergic treatments for motor control in Parkinson's disease.
001875 (2014)	Amaal Al Dakheel [Canada] ; Isabelle Beaulieu-Boire ; Susan H. Fox	Emerging drugs for levodopa-induced dyskinesia.
001888 (2014)	Thérèse Di Paolo [Canada] ; Laurent Grégoire [Canada] ; Dominik Feuerbach [Canada] ; Walid Elbast [Canada] ; Markus Weiss [Canada] ; Baltazar Gomez-Mancilla [Canada]	AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
001A99 (2015)	Laurent Grégoire [Canada] ; Tara Smith [Canada] ; Vijitha Senanayake [Canada] ; Asuka Mochizuki [Japon] ; Edith Miville-Godbout [Canada] ; Dayan Goodenowe [Canada] ; Thérèse Di Paolo [Canada]	Plasmalogen precursor analog treatment reduces levodopa-induced dyskinesias in parkinsonian monkeys.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i -k "Dyskinesia, Drug-Induced (drug therapy)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i  \
                -Sk "Dyskinesia, Drug-Induced (drug therapy)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Dyskinesia, Drug-Induced (drug therapy)
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022